Muhammad A. Khattak

2.2k total citations
44 papers, 1.2k citations indexed

About

Muhammad A. Khattak is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Muhammad A. Khattak has authored 44 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 15 papers in Molecular Biology and 14 papers in Cancer Research. Recurrent topics in Muhammad A. Khattak's work include Cancer Immunotherapy and Biomarkers (20 papers), CAR-T cell therapy research (15 papers) and Cancer Genomics and Diagnostics (14 papers). Muhammad A. Khattak is often cited by papers focused on Cancer Immunotherapy and Biomarkers (20 papers), CAR-T cell therapy research (15 papers) and Cancer Genomics and Diagnostics (14 papers). Muhammad A. Khattak collaborates with scholars based in Australia, United States and Netherlands. Muhammad A. Khattak's co-authors include Elin S. Gray, Mel Ziman, Michael Millward, Tarek Meniawy, Hilary Martin, Michelle R. Pereira, Andrew R. Davidson, Anna Reid, James Freeman and Ashleigh C. McEvoy and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Muhammad A. Khattak

42 papers receiving 1.2k citations

Peers

Countries citing papers authored by Muhammad A. Khattak

Since Specialization

Citations

This map shows the geographic impact of Muhammad A. Khattak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muhammad A. Khattak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muhammad A. Khattak more than expected).

Fields of papers citing papers by Muhammad A. Khattak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Muhammad A. Khattak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muhammad A. Khattak. The network helps show where Muhammad A. Khattak may publish in the future.

Co-authorship network of co-authors of Muhammad A. Khattak

This figure shows the co-authorship network connecting the top 25 collaborators of Muhammad A. Khattak. A scholar is included among the top collaborators of Muhammad A. Khattak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Muhammad A. Khattak. Muhammad A. Khattak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1516MO EVX-01, a personalized cancer vaccine, induces potent T cell responses and durable disease control in advanced melanoma: 2-year follow-up 2025 ·Annals of Oncology ·Muhammad A. Khattak, P.A. Ascierto, Carolina Cimminiello, Michael Chisamore, (unknown), (unknown), Daniela Kleine‐Kohlbrecher, M. Lausen, Michail Pavlidis, Birgitte Rønø, (unknown), Thomas Trolle, (unknown), B.G. Wolthers, (unknown)	0
2	940TiP INTerpath-007: A phase II/III, adaptive, randomized study of neoadjuvant and adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) for treatment of resectable locally advanced (LA) cutaneous squamous cell carcinoma (cSCC) 2024 ·Annals of Oncology ·Rahul Ladwa, (unknown), (unknown), Ann W. Silk, (unknown), (unknown), Muhammad A. Khattak, Robert Meehan, Tomás Posadas, A. Wang, Jupeng Yuan, (unknown), Shlomo A. Koyfman, Dirk Schadendorf	4
3	Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study 2024 ·Journal of Clinical Oncology ·Jason J. Luke, Paolo A. Ascierto, Muhammad A. Khattak, Luis de la Cruz‐Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion‐Sileni, John M. Kirkwood, Caroline Robert, Jean‐Jacques Grob, Federica De Galitiis, Dirk Schadendorf, Matteo S. Carlino, Xi Wu, Mizuho Fukunaga‐Kalabis, Clemens Krepler, Alexander M.M. Eggermont, Georgina V. Long	43
4	Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study 2024 ·The Medical Journal of Australia ·(unknown), Annette M. Lim, Mathias Bressel, Jenny Lee, Rahul Ladwa, Alexander Guminski, Brett Hughes, Samantha Bowyer, Karen Briscoe, S.J. Harris, (unknown), Robert Zielinski, Muhammad Alamgeer, Matteo S. Carlino, (unknown), John Park, Muhammad A. Khattak, Fiona Day, Danny Rischin	8
5	1082O KEYMAKER-U02 substudy 02C: Neoadjuvant pembrolizumab (pembro) and investigational agents followed by adjuvant pembro for stage IIIB-D melanoma 2024 ·Annals of Oncology ·Georgina V. Long, (unknown), Andrew Hill, (unknown), David C. Portnoy, (unknown), Joel E. Cohen, Muhammad A. Khattak, (unknown), Alexander M. Menzies, Gal Markel, Gil Bar‐Sela, (unknown), (unknown), (unknown), Janice M. Mehnert, (unknown), (unknown), (unknown), (unknown)	4
6	Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma 2023 ·Cancer Research ·Reinhard Dummer, Caroline Robert, Richard A. Scolyer, Janis M. Taube, Michael T. Tetzlaff, Andrew Hill, Jean‐Jacques Grob, David C. Portnoy, Célèste Lebbé, Muhammad A. Khattak, Jonathan Cohen, Gil Bar‐Sela, Inderjit Mehmi, Ronnie Shapira Frommer, Nicolás Meyer, Yixin Ren, Mizuho Fukunaga‐Kalabis, Clemens Krepler, Georgina V. Long	19
7	Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study. 2022 ·Journal of Clinical Oncology ·Georgina V. Long, Jason J. Luke, Muhammad A. Khattak, Luis de la Cruz‐Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion‐Sileni, John M. Kirkwood, Caroline Robert, Jean‐Jacques Grob, Federica De Galitiis, Dirk Schadendorf, Matteo S. Carlino, (unknown), Mizuho Fukunaga‐Kalabis, Clemens Krepler, Alexander M.M. Eggermont, Paolo A. Ascierto	6
8	LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial 2021 ·Annals of Oncology ·Jason J. Luke, Piotr Rutkowski, Paola Queirolo, (unknown), Jacek Mackiewicz, (unknown), Luis de la Cruz‐Merino, Muhammad A. Khattak, Dirk Schadendorf, Georgina V. Long, Paolo A. Ascierto, Mario Mandalà, Federica De Galitiis, (unknown), Richard A. Scolyer, John M. Kirkwood, (unknown), Nageatte Ibrahim, (unknown), Alexander M.M. Eggermont	13
9	Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study 2020 ·Frontiers in Oncology ·Muhammad A. Khattak, (unknown), Anna Reid, Ashleigh C. McEvoy, Michael Millward, Mel Ziman, Elin S. Gray	12
10	301MO Genomic HLA as a predictive biomarker for survival among non-small cell lung cancer patient treated with single agent immunotherapy 2020 ·Annals of Oncology ·(unknown), Leslie Calapre, Johnny Lo, (unknown), Samantha Bowyer, Abha Chopra, Mark Watson, Muhammad A. Khattak, Michael Millward, Elin S. Gray	1
11	350P Rheumatologic immune related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy: A Western Australia experience 2020 ·Annals of Oncology ·(unknown), Hilary Martin, Muhammad A. Khattak	1
12	Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel 2019 ·Journal of Molecular Diagnostics ·Elin S. Gray, (unknown), Michelle R. Pereira, Leslie Calapre, (unknown), Darryl Irwin, Brett Chapman, Muhammad A. Khattak, Jeanette Raleigh, Athena Hatzimihalis, Jonathan Cebon, Shahneen Sandhu, Grant A. McArthur, Michael Millward, Mel Ziman, Alexander Dobrovic, Stephen Q. Wong	18
13	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients 2018 ·BMC Cancer ·Ashleigh C. McEvoy, Lydia Warburton, (unknown), (unknown), Leslie Calapre, Michelle R. Pereira, Muhammad A. Khattak, Tarek Meniawy, Michael Millward, Mel Ziman, Elin S. Gray	82
14	Safety of immune check-point inhibitors in patients with autoimmune conditions and advanced cancer 2016 ·Annals of Oncology ·(unknown), (unknown), (unknown), Kynan Feeney, Rachel Roberts‐Thomson, Michael Millward, Muhammad A. Khattak	1
15	Role of First-Line Anti–Epidermal Growth Factor Receptor Therapy Compared With Anti–Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials 2015 ·Clinical Colorectal Cancer ·Muhammad A. Khattak, Hilary Martin, Andrew R. Davidson, Michael Phillips	72
16	Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance 2013 ·World Journal of Urology ·Muhammad A. Khattak, James Larkin	10
17	Endobronchial metastases from renal cell carcinoma: A late manifestation of the disease with an increasing incidence 2012 ·British Journal of Urology ·Muhammad A. Khattak, Rosalie Fisher, Lisa Pickering, Martin Gore, James Larkin	1
18	Survival Differences in Patients With Metastatic Colorectal Cancer and With Single Site Metastatic Disease at Initial Presentation: Results From South Australian Clinical Registry for Advanced Colorectal Cancer 2012 ·Clinical Colorectal Cancer ·Muhammad A. Khattak, Hilary Martin, Carol Beeke, Timothy Price, Scott Carruthers, Susan Kim, Robert Padbury, Christos S. Karapetis	65
19	Metyrapone: a management option for ectopic ACTH syndrome in small cell lung cancer treated with intravenous etoposide 2011 ·BMJ Case Reports ·(unknown), Muhammad A. Khattak, Zafar A Usmani, (unknown), Ken Pittman	3
20	Radiation Induced Leiomyosarcoma Three Decades After Treatment for Wilms’ Tumor 2010 ·World Journal of Oncology ·Muhammad A. Khattak	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact